Emily Field
Stock Analyst at Barclays
(0.92)
# 3,856
Out of 5,182 analysts
15
Total ratings
25%
Success rate
-4.78%
Average return
Main Sectors:
Top Industries:
Stocks Rated by Emily Field
| Stock | Action | Price Target | Current | Upside | Ratings | Updated | |
|---|---|---|---|---|---|---|---|
| PFE Pfizer | Initiates: Underweight | $25 | $26.79 | -6.68% | 1 | Feb 20, 2026 | |
| MRK Merck & Co. | Initiates: Overweight | $140 | $110.23 | +27.01% | 1 | Feb 20, 2026 | |
| GILD Gilead Sciences | Initiates: Equal-Weight | $155 | $127.75 | +21.33% | 1 | Feb 20, 2026 | |
| LLY Eli Lilly and Company | Initiates: Overweight | $1,350 | $868.27 | +55.48% | 1 | Feb 20, 2026 | |
| BMY Bristol-Myers Squibb Company | Initiates: Overweight | $75 | $57.78 | +29.80% | 1 | Feb 20, 2026 | |
| BIIB Biogen | Initiates: Equal-Weight | $185 | $180.67 | +2.40% | 1 | Feb 20, 2026 | |
| AMGN Amgen | Initiates: Equal-Weight | $350 | $340.18 | +2.89% | 1 | Feb 20, 2026 | |
| ABBV AbbVie | Initiates: Overweight | $275 | $197.38 | +39.33% | 1 | Feb 20, 2026 | |
| NVO Novo Nordisk | Downgrades: Equal-Weight | n/a | $41.20 | - | 1 | Jul 30, 2025 | |
| GLPG Galapagos NV | Downgrades: Underweight | n/a | $28.55 | - | 1 | Jan 23, 2025 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Upgrades: Equal-Weight | n/a | $54.22 | - | 4 | Nov 5, 2021 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Upgrades: Overweight | n/a | $783.74 | - | 1 | Oct 19, 2021 |
Pfizer
Feb 20, 2026
Initiates: Underweight
Price Target: $25
Current: $26.79
Upside: -6.68%
Merck & Co.
Feb 20, 2026
Initiates: Overweight
Price Target: $140
Current: $110.23
Upside: +27.01%
Gilead Sciences
Feb 20, 2026
Initiates: Equal-Weight
Price Target: $155
Current: $127.75
Upside: +21.33%
Eli Lilly and Company
Feb 20, 2026
Initiates: Overweight
Price Target: $1,350
Current: $868.27
Upside: +55.48%
Bristol-Myers Squibb Company
Feb 20, 2026
Initiates: Overweight
Price Target: $75
Current: $57.78
Upside: +29.80%
Biogen
Feb 20, 2026
Initiates: Equal-Weight
Price Target: $185
Current: $180.67
Upside: +2.40%
Amgen
Feb 20, 2026
Initiates: Equal-Weight
Price Target: $350
Current: $340.18
Upside: +2.89%
AbbVie
Feb 20, 2026
Initiates: Overweight
Price Target: $275
Current: $197.38
Upside: +39.33%
Novo Nordisk
Jul 30, 2025
Downgrades: Equal-Weight
Price Target: n/a
Current: $41.20
Upside: -
Galapagos NV
Jan 23, 2025
Downgrades: Underweight
Price Target: n/a
Current: $28.55
Upside: -
Nov 5, 2021
Upgrades: Equal-Weight
Price Target: n/a
Current: $54.22
Upside: -
Oct 19, 2021
Upgrades: Overweight
Price Target: n/a
Current: $783.74
Upside: -